tput: No value for $TERM and no -T specified

lf0

Research Desk

Research

BSX

Boston Scientific (BSX) develops medical devices across cardiology, endoscopy, urology, and neuromodulation. It is part of lf0’s Healthcare sector coverage. This page collects every lf0 research note on BSX to date, most recent first, so you can track how the investment case and rating evolve across multiple analysis dates rather than a single snapshot.

Backtesting dashboard with equity curve and drawdown analysis
Quantitative market report dashboard with factor and risk analysis
SEC filing comparison with highlighted document changes

Most Popular Research

EOSEHOLDEos Energy Enterprises Stock Analysis: EOSE Cash Burn, Revenue Growth & Financing RiskEos Energy Enterprises (EOSE) earns a Sell rating as rapid Q1 revenue growth is offset by persistent cash…CASYMade IN USA (USDW) 10-K Changes: Risk Factors Lead 22 June 2026Made IN USA (USDW)'s Risk Factors section changed the most among 14 companies that filed 10-Ks on 22…SOUNSELLSoundHound AI Stock Analysis: Valuation, Cash Burn, Margins & Customer RiskSoundHound AI (SOUN) is rated SELL as rapid revenue growth is offset by weak profitability and ongoing cash…USACHOLDUSA Compression Partners Stock Analysis (NYSE: USAC) | HoldUSA Compression Partners, LP (USAC) is rated Hold as its fixed-fee compression franchise supports steadier cash flow, but…BSXBUYBoston Scientific Stock Analysis: Valuation, Reimbursement Risk, Cash Flow & GrowthBoston Scientific (BSX) earns a Buy rating on double-digit revenue growth, expanding EBITDA, and improving free cash flow.…PATHHOLDUiPath Stock Analysis: Valuation, ARR Growth, Retention & Free Cash FlowUiPath (PATH) earns a HOLD rating as its valuation already reflects a better monetization and margin story. ARR…